U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
First and only FDA-approved treatment option for patients with this type of thyroid cancer Nov 22, 2013, 05:30 ET "We are pleased to be able to offer NEXAVAR as a treatment option for patients with thyroid cancer who are no longer responding to…